Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
F Zagouri, T N Sergentanis, V Koutoulidis, et al.
Breast (Edinburgh, Scotland)
|
February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
T Brodowicz, W J Kostler, R Möslinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
British Journal of Haematology
|
November 11, 1999
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders
G J Locker, S Kapiotis, M Veitl, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 25, 1999
Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions
G J Locker, R M Mader, B Rizovski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
J F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
A Matikas, T Foukakis, V Moebus, et al.
British Journal of Cancer
|
October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
A S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
British Journal of Cancer
|
December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
R Bartsch, A Berghoff, U Pluschnig, et al.
Breast Cancer Research and Treatment
|
April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patients
E S Bergen, C Tichy, A S Berghoff, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
F Zagouri, T N Sergentanis, V Koutoulidis, et al.
Breast (Edinburgh, Scotland)
|
February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
T Brodowicz, W J Kostler, R Möslinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
British Journal of Haematology
|
November 11, 1999
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders
G J Locker, S Kapiotis, M Veitl, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 25, 1999
Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions
G J Locker, R M Mader, B Rizovski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
J F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
A Matikas, T Foukakis, V Moebus, et al.
British Journal of Cancer
|
October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
A S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
British Journal of Cancer
|
December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
R Bartsch, A Berghoff, U Pluschnig, et al.
Breast Cancer Research and Treatment
|
April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patients
E S Bergen, C Tichy, A S Berghoff, et al.
Page
of 7